SCHEMBL3092873

SCHEMBL3092873

CCC(Cc1cnn(Cc2ccccc2Cl)c1)(C(=O)O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.49
LMNA P02545 1/20 0.49
KLKB1 P03952 1/20 0.43
SLC16A3 O15427 6/20 0.41
SLC16A1 P53985 6/20 0.41
MEN1 O00255 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
SCD5 Q86SK9 1/20 0.40
ALDH1A1 P00352 2/20 0.40
ATM Q13315 1/20 0.40
MCTS1 Q9ULC4 4/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091908 0.89 L3MBTL1 (0.47) LMNAKLKB1SCD5ALDH1A1POLB
SCHEMBL15310228 0.84 HSD17B10 (0.49) LMNAKLKB1MEN1KMT2AALDH1A1
SCHEMBL3093669 0.83 TGM2 (0.44) LMNAMEN1KMT2AALDH1A1POLB
SCHEMBL13153130 0.81 LMNA (0.44) HPGDLMNAKLKB1SLC16A3SLC16A1
SCHEMBL3089049 0.81 LMNA (0.50) LMNAKLKB1RAB9ANPC1ALDH1A1
SCHEMBL3093110 0.81 ALDH1A1 (0.47) HPGDLMNAKLKB1SLC16A3SLC16A1
SCHEMBL3097121 0.80 ALDH1A1 (0.50) LMNAMEN1KMT2AALDH1A1ATM
SCHEMBL3090463 0.80 ERCC5 (0.46) SLC16A3SLC16A1ALDH1A1SMN1; SMN2NPSR1
SCHEMBL3096925 0.79 TSHR (0.41) HPGDLMNAKMT2AALDH1A1GAA
SCHEMBL15014079 0.79 LMNA (0.47) HPGDLMNAKLKB1MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 HPGD 1736/4885LMNA 3803/4885KLKB1 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.